TransMedics Group

TMDX Mid Cap

Healthcare · Medical Devices

Updated: Apr 5, 2026, 17:43 UTC

$100.69

+0.29% today

52W: $62.23 – $156.00

52W Low: $62.23 Position: 41% 52W High: $156.00

🔗 Compare Brokers

Key Metrics

P/E Ratio

20.68x

Price-to-Earnings

Forward P/E

27.21x

Forward Price/Earnings

P/S Ratio

5.7x

Price-to-Sales

EV/EBITDA

25.92x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$3.5B

Market Capitalization

Revenue Growth

32.2%

YoY Revenue Growth

Profit Margin

31.43%

Net profit margin

ROE

54.24%

Return on Equity

Beta

2.08

Market sensitivity

Short Interest

41.54%

% of float sold short

Avg. Volume

890,039

Average daily volume

Valuation Analysis

Signal

Fair

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

10 analysts

Avg. Price Target

$161.30

+60.19% upside

Target Range

$130.00 – $190.00

About the Company

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hea

Sector: Healthcare Industry: Medical Devices Country: United States Employees: 898 Exchange: NGM